Table 5 Characteristics of cases of serious skin disorders with current exposure to oral antifungals
From: Risk of serious skin disorders among users of oral antifungals: a population-based study
Current use | Age | Sex | Duration of treatment (days) | Dose (mg) | Diagnosis | Source of diagnosis | Co-medication potentially related with serious skin disorders |
|---|---|---|---|---|---|---|---|
Fluconazole | 45 | F | 18 | 50 | Angioedema | Dermatologist | None |
Fluconazole | 20 | F | 1 | 150 | Erythema multiforme | GP | None |
Griseofulvin | 55 | M | 50 | 500 | Angioedema | GP | Cefalexine, diclofenac |
Itraconazole | 35 | F | 58 | 100 | Angioedema | Dermatologist | Prednisolone |
Itraconazole | 63 | M | 6 | 100 | Erythema multiforme | GP | None |
Terbinafine | 64 | M | 172 | 250 | Angioedema | Dermatologist | None |
Terbinafine | 35 | F | 75 | 250 | Angioedema | GP | None |
Terbinafine | 56 | M | 26 | 250 | Stevens-Johnson syndrome | GP | None |
Terbinafine | 27 | F | 6 | 250 | Erythema multiforme | GP | None |